Special Issues

Special Issue Title: Pathogenesis, Diagnosis and Treatment of Gynaecological Tumors

· Print Special Issue Flyer

· Deadline for manuscript submissions: 31 January 2022

Special Issue Editor

Guest Editor

Prof. Zhe-Sheng (Jason) Chen, MD, PhD

Director, Institute for Biotechnology

College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, NY 11439, USA

Website E-Mail

Interests: Cancer Pharmacology; Drug Discovery; MDR

Prof. Zhong-qiu Lin, MD, PhD

Obstetrics and Gynecology Memorial Hospital of Sun Yat-sen Sun Yat-sen University 107 Yan-jian West Road, Guangzhou510120, Guangdong, China 

Website E-Mail

Interests: Cervical Cancer; Ovarian Cancer; Endometrial Cancer; Vulvar Cancer

Special Issue Information

Dear Colleagues,

  Gynecological tumors are solid tumors happened in the reproductive system of women, including ovarian, cervical cancer, endometrial cancer and others.  These cancers seriously affect the health of women worldwide, and contributing considerably to the global cancer burden. Many conventional anticancer drugs have been used for gynaecological tumors.  For example, cisplatin, paclitaxel, methotrexate, vinorelbine and gemcitabine are often used for the treatment of gynaecological tumors.  However, they may lack therapeutic effects or cause cytotoxic effects. In addition, there are many reports of gynaecological cancer progression and recurrence due to cancer cells that resist to treatments.  
  Significant progress has been made in the treatment of gynecological tumors in recent years. Molecular targeted therapies have emerged as clinically useful drugs for the cure of gynaecological tumors. Molecular mechanisms of carcinogenesis and recurrence of gynecological cancers are gaining better understanding due to recent advances in molecular biology and genomic research. However, there remains a need to uncover biomarkers for prognosis and predictive diagnosis, progression and recurrence of gynecological tumors, and challenges for new therapeutics remain.
  In this topic, we welcome articles for the molecular and cellular biology, biomarkers, diagnostics, and the treatment of gynaecological tumors including conventional chemotherapy, small molecular targeted drugs and monoclonal antibodies for targeted therapy.  In addition, new technologies such as liquid biopsy, mRNA vaccines and gemonic editing therapy focused on gynecological tumors are also welcome.

Prof. Zhe-Sheng (Jason) Chen

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://ejgo.imrpress.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. Submitted papers should be well formatted and use good English.


Cervical Cancer; Ovarian Cancer; Endometrial Cancer; Chemotherapy; Targeted Therapy

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails

Current Issue

  • Volume 42, Issue 5